NEUROLOGY

New Prescription/Referral Prescription Re II

ОТ КЕ ЦІS:

RX: Patient Nam	<u>ıe:</u>		<u>Patient Weight:</u> <u>kg</u>	DOB:
Diagnosis: ICD-10:	Soliris (eculizumab): (neuro dosing)	later, then 1200mg eve		200mg for the fifth dose 1 week ar (inital start with maintenance) sing)
Multiple Sclerosis	Tysabri (natalizumab) Ocrevus (ocrelizumab) (*Pre-Medications Required)	i: Initial dose 300mg del. 2nd dose 300mg IV	ks x1 year (after registering IV for 2.5 hrs for 2.5 hrs to be given after 2	weeks
ICD-10:	Ocrevus Zunovo: (*Premed protocol:)	920mg/23,000units subcontrol of the prior to administration Antihistamine (e.g., deslorato reduce the risk of local at Antipyretic (e.g., acetamino)	eutaneously every 6 months : lent corticosteroid): 20mg adm	x1 year ninistered orally at least 30 mins least 30 mins prior to administration s yretic may also be considered
	Briumvi (ublituximab-	xiiy): Initial dose 150mg	IV then 450mg IV two weeks	
Diagnosis:	IVIG: Gamunex (1) Gammagaro Asceniv (10)	l (10%) Bivigam (10	%) Gammaked(10%)	Gammaplex (10%) Flebogamma DIF (10%)
ICD-10:	Dosage.		g/kg# of days weeks (Optional: Start I	
Migraines ICD-10:	Vyepti (eptinezumab-jjmr): 100 mg IV every 3 months x1 year 300 mg IV every 3 months x1 year			
Myasthenia Gravis ICD-10	Initial dose Ultomiris: (40-59kg) 2,400mg IV, followed by 3,000mg IV 2 weeks later, then 3,000mg IV every 8 weeks (60-99kg) 2,700mg IV, followed by 3,300mg IV 2 weeks later, then 3,300mg IV every 8 weeks (ravulizumab-cwvz): (100kg+) 3,000mg IV, followed by 3,600mg IV 2 weeks later, then 3,600mg IV every 8 weeks Maintenance dose (40-59kg) 3,000mg (60-99kg) 3,300mg (100kg+) 3,600mg IV every 8 weeks Vyvgart: (<120kg) 10mg/kg IV once weekly for 4 weeks (≥120kg) 1200mg IV over 1 hour once weekly for 4 weeks (efgartigimod alfa-fcab) May repeat for cycles (scheduled greater than 50 days from start of previous cycle)			
CIDP (Vyvgart Hytrulo) ICD-10:	**Please provide clinical notes discussing need for recurrent cycles** Vyvgart Hytrulo: (efgartigimod alfa and hyaluronidase-qvfc) **Please provide clinical notes discussing need for recurrent cycles** 1,008 mg / 11,200 units subcutaneously weekly x 4 weeks (Myasthenia Gravis) May repeat for cycles (scheduled greater than 50 days from start of previous cycle) **Please provide clinical notes discussing need for recurrent cycles** 1,008 mg / 11,200 units subcutaneously weekly (CIDP)			
	Rystiggo: (rozanolixizumab-noli)	(<50kg) 420mg SubQ weekl (≥100kg) 840mg subQ week May repeat for cycl **Please provide clinical ne	dy x6	lays from start of previous cycle)
Pre-Medication:	Zofran	: 4mg 8mg IVP	Pepcid IV 20mg IVP	
Solumedrol 125mg I Solu-Cortef 100mg I Others:		ol mg PO 0 mg 975 mg	Benadryl mg 25 mg IV 50 mg PO	PO ANA Kit Protocol OK to use
Physician Signa	turo		NPI #: I	DATE:(Valid for 1 year)
By affixing my signature, I confirm the medical necessity of the aforementioned therapy, products, and services, as well as my responsibility for the patient's care. I have obtained consent to disclose the mentioned details and any relevant medical or patient information concerning this treatment. I grant the pharmacy permission to contact the insurance company on my behalf to secure authorization for the patient. PHYSICIAN INFORMATION				
Physician Name:			Clinic:	
Phone:	Fax:	Email:	Other:	
Office Mailing Address:				
the following	0 1	nsurance attached linical progress notes	Diagnosis(supporting) Medication list	History & Physical Other Test Results

MRI documentation (Tysabri, Ocrevus, Briumvi)

Men ACWY & Men B vaccines (Ultomiris & Soliris)

Serum Immunoglobulins (Ocrevus & Briumvi) AChR antibody (Rystiggo, Vyvgart & Ultomiris) or MuSK antibody (Rystiggo)

CBC & CMP (Ocrevus & Tysabri)

Hep B antigen & Hep B core total (Ocrevus & Briumvi)

JCV antibody (Tysabri)